CD14 and myeloid sarcoma: In contrast to aCD20-treated MS patients, in untreated NMOSD patients, the proportion of two HLADR+CCR7+CD14-CD16- myeloid cell clusters (M16 and M18) negatively correlated with CD4+ T cell reactivity (Fig. 7E).